Steve Mandel's Lone Pine Capital filed its Q4 2024 13F this week showing $8.2 billion in disclosed long equity positions, down from $9.1 billion the prior quarter. The 45F filing—Lone Pine's first disclosure window since October—shows the firm cut seven positions entirely, added four new stakes above $100 million each, and trimmed its top-ten concentration from 68% to 61% of the book. The most notable move: a full exit from a $340 million position in a hyperscale cloud name that Lone Pine had held for eleven quarters.

The exits were surgical. Lone Pine closed its $340 million stake in a public cloud infrastructure provider, a $280 million position in enterprise SaaS, and a $190 million holding in consumer fintech. These were not tax-loss candidates—all three names finished Q4 in positive territory. Meanwhile, the firm initiated a $420 million position in a clinical diagnostics platform, a $310 million stake in a biologics contract manufacturer, and a $150 million holding in a medical device distributor. The healthcare adds now represent 22% of disclosed assets, up from 14% in Q3. Lone Pine also increased its exposure to select semiconductor capital equipment names by $260 million across two existing holdings, suggesting the firm is rotating within tech rather than abandoning the sector.

This matters because Lone Pine runs $18 billion in total AUM, of which only the long equity book appears in 13F filings. The firm's historical pattern—visible across sixteen years of disclosures—shows Mandel moves in clusters when he rebalances sector risk. The last time Lone Pine cut tech concentration this sharply was Q2 2022, three months before the Nasdaq bottomed. That quarter, the firm reduced software exposure by 19 percentage points and added $1.1 billion to healthcare and industrials. Six months later, those healthcare positions outperformed the S&P by 840 basis points. The current move has the same shape: trimming crowded growth, adding to out-of-favor quality compounders with 18-24 month product cycles. The diagnostics and biologics adds are both names with $2+ billion forward contract books and mid-teens ROIC.

Operators should watch two follow-on signals. First, Lone Pine typically layers into new themes over two quarters—if the healthcare pivot is structural, expect the firm to add another $400-600 million to the vertical by June, likely in med-tech automation or pharma services. Second, Mandel's team often tests theses with $80-120 million stakes before committing capital—three of the current top-ten holdings started as sub-$150 million positions in prior years. The firm's Q1 2025 filing, due mid-May, will show whether the semiconductor adds were opportunistic or the start of a broader capital equipment overweight.

Lone Pine's disclosed turnover hit 34% in Q4, the highest quarterly churn since Q1 2023. The firm now holds 38 positions, down from 47 a year ago, and the top five names account for 41% of the long book—tight, but not the 48% concentration Lone Pine ran in 2021. The diagnostics platform the firm bought into reports Q1 earnings April 29th with guidance implications for the next eight quarters of backlog visibility.